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Traditionally considered the hepatic manifestation of the metabolic syndrome, non-alcoholic fatty 
liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide, and 
has dramatically increased in concert with the epidemics of both adult and childhood obesity and 
type 2 diabetes mellitus  [1, 2]. NAFLD includes two distinct conditions with different histological 
features and prognoses: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis 
(NASH); steatohepatitis and significant fibrosis are considered harbingers of adverse hepatic 
outcomes in individuals with NAFLD and are associated with an increased risk for morbidity and 
mortality through hepatic (progression to end-stage liver disease and hepatocellular carcinoma) and 
non-hepatic (mainly cardiovascular) complications [3]. Approximately 30% of adults and 10% of 
children in Western countries have NAFLD, but only a minority, albeit significant, experience 
associated morbidity. What determines the progression to NASH and beyond is not clear. NAFLD 
is characterised by substantial inter-patient variability in terms of severity and rate of progression, 
with fairly rapid disease progression in certain subgroups [4]. The diagnosis of NASH is at present 
based on histological assessment by liver biopsy. The procedure is invasive and associated with a 
risk, even if it is small. However, to date, both the US Food and Drug Administration (FDA) and 
the European Medicines Agency require the demonstration of improvements in liver histological 
endpoints for the market approval of any new pharmacological treatment for NASH. Specifically, 
the FDA does not recognise NAFL as a treatment indication, and any new treatment should focus 
on improving NASH. Although there are no therapeutic interventions currently approved for use in 
NASH, the clinical trial landscape will experience a surge of innovation and exponential growth 
over the coming years.
In this context, the European Association for the Study of the Liver (EASL), the European 
Association for the Study of Diabetes (EASD) and the European Association for the Study of 
Obesity (EASO) joint guidelines for the management of NAFLD [5] represent an important step 
forward, first because they have been developed by organisations with a shared awareness  of the 
multidisciplinary nature of this disease, and second because they set up a common ground to 
optimise the management of patients and fill the knowledge gaps on the course of hepatic and 
extrahepatic comorbidities. In addition, the authors explain that one aim of the guidelines is to 
improve patient care and awareness of the importance of NAFLD, to assist stakeholders in the 
decision-making process by evidence-based data. 
First of all, what patients need to know about this disease?  Patients, particularly obese and diabetic 
individuals, need to be clearly informed that they have a risk of liver-related complications and 
death driven by NASH, similar to how they are informed of cardiovascular, metabolic and kidney 
complications..
Ultrasound-diagnosed NAFLD is not associated with increased liver-related mortality, but in NASH 
liver disease is the third most common cause of death after CVD and cancer, and the risk is 
increased tenfold compared with that for the general population [2]. Indeed, NASH resembles 
hepatitis C virus-related chronic liver disease in terms of its insidious onset and indolent course, 
often diagnosed at the time of cirrhosis,particularly in patients with type 2 diabetes. A recent study 
in Hong Kong reported that 73% of the diabetic patients at primary care and hospital clinics had 
fatty liver and 18% had increased liver stiffness by transient elastography suggestive of advanced 
fibrosis independently of liver enzymes [6]. 
Information is an ethical duty and it is the first step toward prevention, as patients should avoid 
other risk factors for liver disease, such as occasional alcohol abuse or potentially hepatotoxic 
drugs. While this can translate into a case-by-case screening for NASH in adults, where the liver-
related risk must always be weighed up against the cardiovascular risk, children represent the most 
vulnerable population that does have the potential to develp the full spectrum of complications 
associated with NASH [7] and hence deserves an indepth approach, according to what suggested by 
the guidelines. 
That said, what sets NAFLD apart from other common liver diseases is the sheer volume of patients 
with this diease and the lack of a definite therapeutic modality. In this context, the major focus of 
clinical care for patients with NAFLD is discerning those at highest risk for the complications of 
advanced liver disease. The guidelines recommend that individuals with obesity or any component 
of the metabolic syndrome should have an ultrasound and steatosis biomarkers and liver enzymes 
measured, particularly patients with type 2 diabetes, for whom the presence of NAFLD should be 
looked for irrespective of liver enzyme levels [5]. On the one hand, this would include the full 
spectrum of NAFLD in the real life setting, the most important piece of information missing so far, 
but on the other, this  would represent an extreme challenge in terms of the resources of national 
heathcare systems. A cost–utility analysis of NASH screening is hampered by uncertainties 
surrounding the non-invasive markers of liver damage and the lack of effectiveness data relating to 
the impact of treatment on fibrosis in patients with NASH. In an exploratory analysis on the use of 
non- invasive tests to determine referral to tertiary care [8], the analysis of the incremental cost per 
correct positive diagnosis found that most of the tests were dominated by liver biopsy; however, the 
analysis per correct negative diagnosis found that fibrosis 4 calculator (FIB-4) (high cut-off) and 
NAFLD Fibrosis Score (NAFLD-FS)(high cut-off) had an incremental cost-effectiveness ratio of 
below £1, while the one for biopsy was £145.39. Another cost-utility analysis in middle-aged 
diabetic individuals [9], which compared a screening strategy for NASH (one-time liver ultrasound 
in all and liver biopsies in those with fatty liver) vs no screening, found that the first led to a 12.9% 
reduction in incident cirrhosis and an 11.9% decrease in liver-related deaths, but was associated 
with 0.02 fewer quality-adjusted life years because of disutility associated with treatment (i.e. 
weight gain associated with pioglitazone). The model suggests that screening for NASH is likely to 
be cost-effective only when medications with mild side effects, even with those with modest 
efficacy, become available. Although no such medication is currently available, there has been rapid 
development in this field, with over 200 studies listed on ClinicalTrials.gov and encouraging results 
from recent trials. 
In the meantime, how can assessments be implemented, particularly in the primary care setting? 
First, the non-invasive measures of steatosis, such as the fatty liver index (FLI), can easily be 
calculated from clinical and biochemical data to screen for presence/absence of NAFLD. 
Assessment of liver enzymes incurs additional costs, but not very different from those associated 
with screening for cardiovascular or kidney damage. While abnormal liver function test (LFT) 
results are an indication for specialist referral anyway, problems come for “normal” LFTs as these 
patients can experience liver problems as well. However, the absolute value of alanine transaminase 
(ALT) can still be a prognostic indicator. In adults, the upper limit of ‘normal’ ALT has been 
reduced to 30 U/l for men and 19 U/l for women [10], while according to the SAFETY study [11], 
the commonly proposed cut-off values for an elevated ALT level should be reduced to 25 U/l in 
boys and 22 U/l in girls. Furthermore, the same easily available variables (clinical, anthropometric 
and laboratory) can be used in the two above-mentioned scoring systems, FIB-4 and NAFLD-FS, to 
exclude severe NASH. The NAFLD-FS is calculated based on age, BMI, hyperglycaemia or 
diabetes, aspartate transaminase (AST)/ALT, platelets, and albumin (www.nafldscore.com), while 
the FIB-4 is based on age, AST, ALT and platelets [12]. The presence, duration and severity of 
obesity and type 2 diabetes, along with the presence of other risk factors (such as familial history of 
liver disease) or any signs and symptoms of chronic liver disease, are important indicators of 
possible NASH.
What is the ultimate aim of these guidelines? First of all, to harmonise a myriad of approaches, 
languages and thinking about this intriguing and potentially lethal liver disease. The bare truth is 
that we need to know more about NAFLD, as dramatically underlined by the lack of non-invasive 
biomarkers of NASH, which hampers clinical practice and seriously impedes drug development. 
The most successful development programmes are those where the pathogenesis and the natural 
history of the disease are well understood, but hepatologists see only the extreme end of the 
spectrum of NAFLD. We need to find a common ground where all the major players in the 
metabolic field can cooperate, sharing resources, clinical data and patient samples, to tackle this 
modern-day disease and translate ‘disease mongering’ into an effective way forward for the patients 
and for the healthcare systems.
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